<p>多伦多，2025 年 12 月 30 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣布已完成之前宣布的向加拿大投资者进行的普通股私募（“发行”）。</p>
<p>根据此次发行，公司共发行了 921,428 股普通股，发行价格为每股 7.00 美元，合计募集资金约 645 万美元。</p>
<p>根据此次发行出售的普通股在发行结束日期后，需遵循加拿大证券法的四个月加一天的持有期。</p>
<p>公司计划将此次发行的净收益用于扩大销售和市场营销、营运资金、研发、战略交易及一般企业用途。</p>
<p>此次发行的证券未在美国证券法下注册，且在未注册或不适用的美国注册要求及相关州证券法的豁免情况下，不能在美国境内或向美国人士提供或出售该证券。公司已同意在发行结束日期后的四个月内向美国证券交易委员会提交注册声明，以注册在私募中发行的普通股的转售。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或其他司法管辖区进行公司证券的销售，除非在该州或其他司法管辖区的证券法下注册或合格。</p>
<p><strong>关于 Profound Medical Corp.</strong></p>
<p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
<p>Profound 正在商业化 TULSA-PRO®，这是一种结合实时 MRI、增强型人工智能规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。TULSA 程序™使用 TULSA-PRO 系统进行，具有成为整个前列腺疾病谱的主流治疗方式的潜力；包括低、中、高风险前列腺癌；同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅有 BPH 的男性；以及需要针对放射性复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声波吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口、无辐射的 “一次性” 程序，在一个会话中完成，持续几个小时。几乎所有形状和大小的前列腺都可以安全、有效且高效地使用 TULSA 治疗。该程序不伴随出血；无需住院；大多数 TULSA 患者报告迅速恢复到正常生活。TULSA-PRO 已获得 CE 标志、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 许可。</p>
<p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 标志，用于治疗子宫肌瘤、子宫内膜异位症、骨转移疼痛缓解、纤维瘤和骨肉瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于非侵入性治疗子宫肌瘤，并在美国获得人道设备豁免下的 FDA 批准，用于治疗骨肉瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，如非侵入性消融腹部癌症和癌症治疗的高温疗法。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期使用发行所得款项及计划注册普通股相关的声明。通常，但并非总是，前瞻性声明可以通过使用诸如 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或者声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能会” 或 “将会” 被采取、发生或实现。这些声明基于 Profound 管理层当前的预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期发生，甚至可能根本不发生，并且可能因影响公司的已知和未知风险因素和不确定性而有实质性差异。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或打算的内容有所不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险已在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中描述，相关文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，否则前瞻性声明仅在作出声明的日期有效，Profound 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律另有要求的情况除外。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>Stephen Kilmer</p>
<p>投资者关系</p>
<p>skilmer@profoundmedical.com</p>
<p>电话：647.872.4849</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTNNQ00zTXpRd01qRXpJekl3TVRnMU5EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTNNQ00zTXpRd01qRXpJekl3TVRnMU5EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjgxODVhNDMtYWY2Yy00OTI5LTgzNWEtYWUwYzYxYTI4YTRlLTEwMzAxMTktMjAyNS0xMi0zMC1lbg==/tiny/Profound-Medical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjgxODVhNDMtYWY2Yy00OTI5LTgzNWEtYWUwYzYxYTI4YTRlLTEwMzAxMTktMjAyNS0xMi0zMC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

PROF

<p>Profound Medical Corp. 已完成 921,428 股普通股的私募配售，每股价格为 7.00 美元，筹集了约 645 万美元。所得款项将用于销售和市场扩展、营运资金、研发以及一般企业用途。这些股票根据加拿大证券法规定，需遵循四个月的持有期。Profound 以其人工智能驱动的无切口前列腺疾病治疗方案而闻名，包括 TULSA-PRO 系统和 Sonalleve 平台，适用于多种医疗应用</p>

<p>TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong> (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).</p>
<div class="lb-trans"><p>多伦多，2025 年 12 月 30 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣布已完成之前宣布的向加拿大投资者进行的普通股私募（“发行”）。</p>
</div><p>Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45 million.</p>
<div class="lb-trans"><p>根据此次发行，公司共发行了 921,428 股普通股，发行价格为每股 7.00 美元，合计募集资金约 645 万美元。</p>
</div><p>The common shares sold pursuant to the Offering are subject to a hold period of four months plus one day from the closing date of the Offering under Canadian securities laws.</p>
<div class="lb-trans"><p>根据此次发行出售的普通股在发行结束日期后，需遵循加拿大证券法的四个月加一天的持有期。</p>
</div><p>The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.</p>
<div class="lb-trans"><p>公司计划将此次发行的净收益用于扩大销售和市场营销、营运资金、研发、战略交易及一般企业用途。</p>
</div><p>The securities being offered under the Offering have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement within four months from the closing date of the Offering.</p>
<div class="lb-trans"><p>此次发行的证券未在美国证券法下注册，且在未注册或不适用的美国注册要求及相关州证券法的豁免情况下，不能在美国境内或向美国人士提供或出售该证券。公司已同意在发行结束日期后的四个月内向美国证券交易委员会提交注册声明，以注册在私募中发行的普通股的转售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Company’s securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或其他司法管辖区进行公司证券的销售，除非在该州或其他司法管辖区的证券法下注册或合格。</p>
</div><p><strong>About Profound Medical Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 Profound Medical Corp.</strong></p>
</div><p>Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.</p>
<div class="lb-trans"><p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
</div><p>Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).</p>
<div class="lb-trans"><p>Profound 正在商业化 TULSA-PRO®，这是一种结合实时 MRI、增强型人工智能规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。TULSA 程序™使用 TULSA-PRO 系统进行，具有成为整个前列腺疾病谱的主流治疗方式的潜力；包括低、中、高风险前列腺癌；同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅有 BPH 的男性；以及需要针对放射性复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声波吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口、无辐射的 “一次性” 程序，在一个会话中完成，持续几个小时。几乎所有形状和大小的前列腺都可以安全、有效且高效地使用 TULSA 治疗。该程序不伴随出血；无需住院；大多数 TULSA 患者报告迅速恢复到正常生活。TULSA-PRO 已获得 CE 标志、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 许可。</p>
</div><p>Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>
<div class="lb-trans"><p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 标志，用于治疗子宫肌瘤、子宫内膜异位症、骨转移疼痛缓解、纤维瘤和骨肉瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于非侵入性治疗子宫肌瘤，并在美国获得人道设备豁免下的 FDA 批准，用于治疗骨肉瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，如非侵入性消融腹部癌症和癌症治疗的高温疗法。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds from the Offering and the intended registration of the common shares. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.</p>
<div class="lb-trans"><p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期使用发行所得款项及计划注册普通股相关的声明。通常，但并非总是，前瞻性声明可以通过使用诸如 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或者声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能会” 或 “将会” 被采取、发生或实现。这些声明基于 Profound 管理层当前的预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期发生，甚至可能根本不发生，并且可能因影响公司的已知和未知风险因素和不确定性而有实质性差异。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或打算的内容有所不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险已在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中描述，相关文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，否则前瞻性声明仅在作出声明的日期有效，Profound 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律另有要求的情况除外。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Stephen Kilmer</p>
<div class="lb-trans"><p>Stephen Kilmer</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>skilmer@profoundmedical.com</p>
<div class="lb-trans"><p>skilmer@profoundmedical.com</p>
</div><p>T: 647.872.4849</p>
<div class="lb-trans"><p>电话：647.872.4849</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ETTNNQ00zTXpRd01qRXpJekl3TVRnMU5EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODM3MCM3MzQwMjEzIzIwMTg1NDc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NjgxODVhNDMtYWY2Yy00OTI5LTgzNWEtYWUwYzYxYTI4YTRlLTEwMzAxMTktMjAyNS0xMi0zMC1lbg==/tiny/Profound-Medical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NjgxODVhNDMtYWY2Yy00OTI5LTgzNWEtYWUwYzYxYTI4YTRlLTEwMzAxMTktMjAyNS0xMi0zMC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

Profound Medical Corp.宣布完成私募配售 | PROF 股票新闻